Opsona Therapeutics Ltd.
This article was originally published in Start Up
Executive Summary
Opsona Therapeutics is focusing on Toll-like receptors, which control the activity of regulatory T cells, signaling the presence of infection and triggering the inflammatory immune response. The company will identify key preclinical candidates (either in-house or licensed-in) and take them to development points of value before partnering. The Trinity College spin-out has struck its first two deals: with Wyeth Pharmaceuticals and with Phylogica.